Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01787409 · ClinicalTrials.gov registry record · NA

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

A NA study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, sponsored by Mayo Clinic.

Active
Registry status
NA
Development phase
565
Enrollment target
5
Study locations

NCT01787409: Active NA study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, sponsored by Mayo Clinic.

NCT01787409 is a NA study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 565 participants, above the 179-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (216% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01787409, a NA study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
565 participants
Enrollment target
5
Study locations

Study Summary

This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.

Primary Outcome

The proportion of successes will be estimated separately in the groups by the number of successes divided by the total number of evaluable patients. 95% confidence intervals for the true success proportion will be calculated by the exact binomial method.

Interventions

  • DIETARY_SUPPLEMENT Cholecalciferol
  • OTHER Laboratory Biomarker Analysis

Study Locations (5)

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Georgia

  • Emory University/Winship Cancer Institute - Atlanta

Iowa

  • University of Iowa/Holden Comprehensive Cancer Center - Iowa City

Minnesota

  • Mayo Clinic - Rochester

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 565 participants
Start Date 2013-03-06
Est. Completion 2028-06-30
Phase NA
Mayo Clinic

2,844 total trials

What the registry record for NCT01787409 still lists

NCT01787409 is an interventional study that assigns participants to a tested intervention. The registered 565 participants enrollment target is mid-sized for trials with a published cap, above the 179-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (216% higher).

The record links to 10 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Cholecalciferol is the first listed.

NCT01787409 lists 5 locations in 5 states (Arizona, Georgia, Iowa).

Frequently Asked Questions

What is clinical trial NCT01787409 about?

NCT01787409 is a clinical study titled "Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency". This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficien...

What is the current status of trial NCT01787409?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 565 participants. The study started on 2013-03-06. Estimated completion is 2028-06-30.

What conditions does trial NCT01787409 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma.

What interventions are being tested in trial NCT01787409?

The interventions under investigation include: Cholecalciferol (DIETARY_SUPPLEMENT), Laboratory Biomarker Analysis (OTHER).

Who is sponsoring clinical trial NCT01787409?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01787409 being conducted?

This trial has 5 study locations across Arizona, Georgia, Iowa, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01787409's enrollment target sits among peer trials

565 16th of 187 higher than 172 of 187 other Chronic Lymphocytic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06146725 · 564 participants

    The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

  • NCT06188520 · 564 participants · Phase 1

    A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

  • NCT06628453 · 564 participants · NA

    CGM for Management of Type 2 Diabetes in Pregnancy

  • NCT07125326 · 564 participants · NA

    How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01787409, the US trial registry maintained by the National Library of Medicine. NCT01787409 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.